{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:26:23Z","timestamp":1787563583973,"version":"build-2736575974"},"reference-count":35,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: While triptans remain the standard of care for moderate-to-severe migraine, the high discontinuation rates and remarkably low prescribing rates of triptans reflect suboptimal therapeutic optimization. Methods: This retrospective cohort study utilized data from Maccabi Healthcare Services (MHS), the second-largest healthcare provider in Israel, spanning 10 years (2012\u20132022). We identified na\u00efve triptan users aged 21 years or older and evaluated triptan initiation and discontinuation patterns. Median time to discontinuation was assessed using Kaplan-Meier curves. Results: Of 2.8 million MHS members, 91,619 (3.4%) individuals had at least one triptan dispensation or prescription during the study period, including 41,297 triptan-na\u00efve patients who met the study criteria. The median age at triptan initiation was 38.4 years (interquartile range: 28.2\u201348.0), and 75.6% were female. Overall, the median time to discontinuation was 7.7 months (95% confidence interval: 7.1\u20138.4). Discontinuation occurred in 70% of the cohort, with approximately 74% of triptan users purchasing only a single triptan formulation throughout the study period. Subgroup analyses by age, sex, socioeconomic status, and anxiety\/depression prevalence demonstrated consistent discontinuation patterns across demographic and clinical characteristics, with median time to discontinuation remaining under 12 months in nearly all subgroups. Annual median time to discontinuation consistently remained under 12 months throughout the study period while showing a significant decreasing trend. Conclusions: The low rates of triptan use and high discontinuation rates suggest a possible undertreatment of migraine in Israel. These results highlight the need for improved patient and physician education, and enhanced follow-up protocols.<\/jats:p>","DOI":"10.3390\/jcm15041437","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:48:34Z","timestamp":1770889714000},"page":"1437","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Triptan Use and Potential Undertreatment in Migraine: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3264-3380","authenticated-orcid":false,"given":"Yael","family":"Barer","sequence":"first","affiliation":[{"name":"Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv 6812509, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Hoshen","sequence":"additional","affiliation":[{"name":"Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv 6812509, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9875-3550","authenticated-orcid":false,"given":"Sivan","family":"Gazit","sequence":"additional","affiliation":[{"name":"Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv 6812509, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sharman Moser","sequence":"additional","affiliation":[{"name":"Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv 6812509, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matanya","family":"Tirosh","sequence":"additional","affiliation":[{"name":"Pfizer Pharmaceuticals Israel LTD, Herzliya 4672509, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danna","family":"Davivdovici","sequence":"additional","affiliation":[{"name":"Pfizer Pharmaceuticals Israel LTD, Herzliya 4672509, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9728-9733","authenticated-orcid":false,"given":"Erel","family":"Domany","sequence":"additional","affiliation":[{"name":"Department of Neurology and Headache Clinic, Rambam Medical Center, Haifa 3109601, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amnon","family":"Mosek","sequence":"additional","affiliation":[{"name":"Headache and Facial Pain Clinic, Hod Hasharon 454529248, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","article-title":"Global epidemiology of migraine and its implications for public health and health policy","volume":"19","author":"Steiner","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(24)00476-8","article-title":"Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950\u20132021, and the impact of the COVID-19 pandemic: A comprehensive demographic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Schumacher","year":"2024","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1017\/cjn.2021.75","article-title":"The Burden of Illness of Migraine in Canada: New Insights on Humanistic and Economic Cost","volume":"49","author":"Amoozegar","year":"2022","journal-title":"Can. J. Neurol. Sci.\/J. Can. Sci. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"111557","DOI":"10.1016\/j.biopha.2021.111557","article-title":"Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine","volume":"139","author":"Khan","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"03331024241305381","DOI":"10.1177\/03331024241305381","article-title":"Evidence-based guidelines for the pharmacological treatment of migraine","volume":"45","author":"Ornello","year":"2025","journal-title":"Cephalalgia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1212\/CON.0000000000001418","article-title":"Preventive Treatment of Migraine","volume":"30","author":"Lipton","year":"2024","journal-title":"Continuum"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Isteni\u010d, S., Jerman, A., Pu\u0161nik, L., Pintari\u010d, T.S., and Umek, N. (Reg. Anesth. Pain Med., 2025). Transnasal spread of bupivacaine into the pterygopalatine fossa following endoscopically assisted cotton swab placement: A cadaveric study, Reg. Anesth. Pain Med., Online ahead of print.","DOI":"10.1136\/rapm-2025-106553"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","article-title":"Migraine","volume":"391","author":"Dodick","year":"2018","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/head.12404","article-title":"Treatment persistence and switching in triptan users: A systematic literature review","volume":"54","author":"Messali","year":"2014","journal-title":"Headache"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/0333102420905307","article-title":"Acute treatment patterns in patients with migraine newly initiating a triptan","volume":"40","author":"Lipton","year":"2020","journal-title":"Cephalalgia"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Deighton, A.M., Harris, L.A., Johnston, K., Hogan, S., Quaranta, L.A., L\u2019Italien, G., and Coric, V. (2021). The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: A systematic literature review. BMC Neurol., 21.","DOI":"10.1186\/s12883-021-02451-x"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/0333102410383058","article-title":"Triptan persistency among newly initiated users in a pharmacy claims database","volume":"31","author":"Rajagopalan","year":"2011","journal-title":"Cephalalgia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s10194-023-01676-0","article-title":"Triptan non-response in specialized headache care: Cross-sectional data from the DMKG Headache Registry","volume":"24","author":"Ruscheweyh","year":"2023","journal-title":"J. Headache Pain"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0333102412449929","article-title":"Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases","volume":"32","author":"Chen","year":"2012","journal-title":"Cephalalgia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1129-2377-15-48","article-title":"Treatment adherence among new triptan users: A 2-year cohort study in Taiwan","volume":"15","author":"Chen","year":"2014","journal-title":"J. Headache Pain"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Khan, K., Arain, M.I., Asghar, M.A., Rehman, A.A., Ghoto, M.A., Dayo, A., Imtiaz, M.S., Rana, M.H., and Asghar, M.A. (2021). Analysis of treatment cost and persistence among migraineurs: A two-year retrospective cohort study in Pakistan. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0248761"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1038\/s41598-022-12545-2","article-title":"Low adherence to the guideline for the acute treatment of migraine","volume":"12","author":"Olesen","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3331024241269758","DOI":"10.1177\/03331024241269758","article-title":"Cost of illness and labour market disaffiliation among patients with migraine discontinuing triptan treatment: A Danish nationwide register study from 1995 to 2021","volume":"44","author":"Ashina","year":"2024","journal-title":"Cephalalgia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/head.14968","article-title":"Cardiovascular risk and triptan usage among patients with migraine","volume":"65","author":"Peles","year":"2025","journal-title":"Headache J. Head Face Pain"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s10194-025-01961-0","article-title":"Epidemiology of clinically significant migraine in Israel: A retrospective database study","volume":"26","author":"Shifrin","year":"2025","journal-title":"J. Headache Pain"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s10194-022-01513-w","article-title":"Migraine epidemiology and comorbidities in Southern Israel: A clinical database study in a universal health coverage setting","volume":"23","author":"Peles","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1526-4610.2006.00435.x","article-title":"Triptans\u2014Why once?","volume":"46","author":"Ifergane","year":"2006","journal-title":"Headache J. Head Face Pain"},{"key":"ref_24","unstructured":"(2026, January 07). Characterization and Classification of Geographical Units by the Socio-Economic Level of the Population, 2019, Available online: https:\/\/www.cbs.gov.il\/en\/publications\/Pages\/2023\/socio-2019-e.aspx."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.maturitas.2020.11.005","article-title":"Long-term effects of gestational diabetes on bone mineral density and fracture risk: Analysis of the Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk) population-based study","volume":"144","author":"Ahmeidat","year":"2021","journal-title":"Maturitas"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jns.2016.11.071","article-title":"Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants","volume":"372","author":"Woldeamanuel","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(17)30636-0","article-title":"Health and health care in Israel: An introduction","volume":"389","author":"Clarfield","year":"2017","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13584-020-00417-x","article-title":"National initiatives to promote quality of care and patient safety: Achievements to date and challenges ahead","volume":"9","author":"Dreiher","year":"2020","journal-title":"Isr. J. Health Policy Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/head.14854","article-title":"Relative frequency, characteristics, and disease burden of patients with migraine unsuitable for triptan treatment: A systematic literature review","volume":"65","author":"Lipton","year":"2025","journal-title":"Headache"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1177\/0333102421991809","article-title":"Twenty-five years of triptans\u2014A nationwide population study","volume":"41","author":"Davidsson","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/head.12198","article-title":"Identifying the factors underlying discontinuation of triptans","volume":"54","author":"Wells","year":"2014","journal-title":"Headache"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamaneurol.2017.5144","article-title":"Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants with Serotonin Syndrome","volume":"75","author":"Orlova","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1526-4610.2010.01691.x","article-title":"The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper","volume":"50","author":"Evans","year":"2010","journal-title":"Headache"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-023-02650-7","article-title":"Unmet Needs in the Acute Treatment of Migraine","volume":"41","author":"Bentivegna","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/pds.4723","article-title":"Patterns of initial migraine treatment in Denmark: A population-based study","volume":"28","author":"Thomsen","year":"2019","journal-title":"Pharmacoepidemiol. Drug Saf."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1437\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:13:08Z","timestamp":1771045988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15041437"],"URL":"https:\/\/doi.org\/10.3390\/jcm15041437","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}